Blackstone Affiliate Holds 7.6% Of Autolus After Warrants Expire
BXLS V - Autobahn's ownership update came from expired warrants, rather than buying or selling shares.
BXLS V - Autobahn, a Blackstone-affiliated healthcare investor, reported a 7.6% stake in Autolus Therapeutics, which makes treatments using genetically reprogrammed immune cells, in an amended SEC ownership filing Tuesday. The update followed Friday's expiration of warrants covering 3,265,306 American Depositary Shares, rather than a purchase or sale of Autolus shares.
The Shares Behind The Stake
BXLS V - Autobahn directly holds 20,485,611 depositary shares, each representing one Autolus ordinary share. Warrants give their holders the right to obtain shares; their expiration changed the reported beneficial-ownership calculation without a share trade by the reporting investors.
The 7.6% figure uses 269,662,540 ordinary shares outstanding as of August 10, 2026. Autolus supplied that share count in a prospectus filed September 22, 2026, so the ownership percentage rests on that dated denominator.
The reporting investors listed sole voting and disposal power over the shares held directly by BXLS V - Autobahn. Blackstone-related entities also reported beneficial ownership through their relationships with the partnership; those entries refer to the same holding, rather than separate blocks of Autolus shares.
BXLS V - Autobahn invests in and helps early-stage and growth-oriented healthcare and life-sciences businesses. Its Autolus ownership record began with a November 16, 2021 disclosure and was amended on December 13, 2022, and May 21, 2024.
AUCATZYL Anchors Autolus's Business
Autolus's commercial therapy, AUCATZYL, treats adults whose B-cell precursor acute lymphoblastic leukemia has returned or resisted treatment. The company genetically reprograms patients' T cells—a type of immune cell—to target disease.
Autolus sells AUCATZYL in the United States and United Kingdom, where only authorized specialist treatment centers can administer it. Production takes place at the company's Nucleus facility in Stevenage, U.K.; the therapy is available through the National Health Service in England and Wales.
Beyond AUCATZYL, Autolus develops cell therapies for other blood cancers, solid tumors and autoimmune diseases, including lupus and multiple sclerosis. Autolus's market capitalization was $351 million as of 4:42 p.m. ET Tuesday.
For this ownership update, the change was the expiration of rights to obtain shares; BXLS V - Autobahn still directly held 20,485,611 depositary shares.
Sources
- SCHEDULE 13D/A — BXLS V - Autobahn L.P. re: Autolus Therapeutics plc (AUTL) — SEC EDGAR
- SCHEDULE 13D/A Exhibit 99.1 — SEC EDGAR
- SCHEDULE 13D/A Exhibit 99.2 — SEC EDGAR
